Interim results from a phase 3b clinical trial in Europe showed Roclanda was non-inferior to Ganfort, according to a press release.
The Mercury 3 trial compared IOP reduction in patients with open-angle glaucoma or ocular hypertension. The randomized, masked study included about 430 patients who received study medication once daily each evening.
The 90-day topline data showed that Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution, Aerie Pharmaceuticals), marketed as Rocklatan in the United States, met the overall study objective by demonstrating non-inferiority to Ganfort
Uncategorized